SERES THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.918 USD | -3.27% |
|
+2.50% | -34.41% |
| May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
| May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
Presentation Operator MessageOperator (Operator)Welcome to the Seres Therapeutics First Quarte...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Calendar
2024-07-29
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.949
USD
Average target price
6.2
USD
Spread / Average Target
+553.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.41% | 144M | |
| +8.18% | 115B | |
| +13.16% | 107B | |
| -13.43% | 22.31B | |
| -3.99% | 21.6B | |
| -5.63% | 18.23B | |
| -39.93% | 17.62B | |
| +7.68% | 14.26B | |
| +33.69% | 12.37B | |
| -28.24% | 8.28B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Transcript : Seres Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022